Advertisement

Topics

Gilead gets FDA priority review for bictegravir regimen for HIV treatment

06:12 EDT 11 Aug 2017 | Pharmaceutical Business Review

The US Food and Drug Administration (FDA) has granted priority review for Gilead Sciences’ New Drug Application (NDA) for its investigational, fixed-dose combination of bictegravir (50mg) (BIC) and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection.

Original Article: Gilead gets FDA priority review for bictegravir regimen for HIV treatment

NEXT ARTICLE

More From BioPortfolio on "Gilead gets FDA priority review for bictegravir regimen for HIV treatment"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...